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the metabolic syndrome in the morbidly obese:
a cross-sectional study
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Abstract
Background: The biological mechanisms in the association between the metabolic syndrome (MS) and various
biomarkers, such as 25-hydroxyvitamin D (vit D) and magnesium, are not fully understood. Several of the proposed
predictors of MS are also possible predictors of parathyroid hormone (PTH). We aimed to explore whether PTH is a
possible mediator between MS and various possible explanatory variables in morbidly obese patients.
Methods: Fasting serum levels of PTH, vit D and magnesium were assessed in a cross-sectional study of 1,017
consecutive morbidly obese patients (68% women). Dependencies between MS and a total of seven possible
explanatory variables as suggested in the literature, including PTH, vit D and magnesium, were specified in a path
diagram, including both direct and indirect effects. Possible gender differences were also included. Effects were
estimated using Bayesian path analysis, a multivariable regression technique, and expressed using standardized
regression coefficients.
Results: Sixty-eight percent of the patients had MS. In addition to type 2 diabetes and age, both PTH and serum
phosphate had significant direct effects on MS; 0.36 (95% Credibility Interval (CrI) [0.15, 0.57]) and 0.28 (95% CrI
[0.10,0.47]), respectively. However, due to significant gender differences, an increase in either PTH or phosphate
corresponded to an increased OR for MS in women only. All proposed predictors of MS had significant direct
effects on PTH, with vit D and phosphate the strongest; -0.27 (95% CrI [-0.33,-0.21]) and -0.26 (95% CrI [-0.32,-0.20]),
respectively. Though neither vit D nor magnesium had significant direct effects on MS, for women they both
affected MS indirectly, due to the strong direct effect of PTH on MS. For phosphate, the indirect effect on MS,
mediated through serum calcium and PTH, had opposite sign than the direct effect, resulting in the total effect on
MS being somewhat attenuated compared to the direct effect only.
Conclusion: Our results indicate that for women PTH is a plausible mediator in the association between MS and a
range of explanatory variables, including vit D, magnesium and phosphate.
Background
The metabolic syndrome (MS) is a clustering of risk fac-
tors including abdominal obesity, insulin resistance and
elevated blood pressure [1], and it has an increased inci-
dence among the obese part of the population; a pro-
portion which is steadily growing [2,3]. Having the MS
is associated with increased risk of type 2 diabetes, car-
diovascular disease [4] and chronic kidney disease [5].
A better understanding the possible biological mechanisms
related to the occurrence of MS is therefore of major
interest.
Age and diabetes are well-known to be associated with
MS [6]. A number of studies indicate that MS is also
related to various biomarkers such as serum 25-hydro-
xyvitamin D (vit D), magnesium and calcium [7-11]. Ele-
vated levels of parathyroid hormone (PTH) have been
reported together with MS [12,13]. In studies focusing
on other variables, it has been debated whether these
variables should be adjusted for PTH in the analyses
[14-16]. Indeed, the reported effects of PTH are contra-
dictory. A recent publication on morbidly obese subjects
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found a relationship between MS and PTH [17], which
is in contrast with a previous study [18].
Establishing the role of PTH in relation to MS is com-
plicated by the fact that several of the proposed predic-
tors of MS are also known to be associated with PTH.
The synthesis and secretion of PTH is tightly regulated
by serum levels of calcium and phosphate, but also
serum concentrations of vit D and magnesium influence
PTH levels [19,20], and a statistically significant negative
correlation between vit D and PTH has been reported
[17]. Studies further indicate that gender differences
should be taken into account; increasing PTH levels
have been reported to be associated with MS in older
men, but not in women and younger men [12,13].
The mechanisms explaining the association between
MS and various biomarkers are not well understood,
and focusing solely on direct effects might overlook
clinically interesting indirect effects. The above refer-
ences indicate that PTH might be a mediator for MS,
highlighting the need for analytical approaches that
include both direct and indirect effects.
The aim of this study was to explore whether PTH
might have a mediating role in the association between
MS and a series of possible explanatory variables in
morbidly obese patients. Dependencies between MS and
a series of variables suggested in the literature were
depicted in a path diagram. Effect sizes were estimated
by path analysis, a regression technique where several
multiple regression models are combined, allowing vari-
ables to be both an outcome and an explanatory variable
in the same model [21].
Methods
Study population
Individuals having BMI ≥40 kg/m², or a BMI ≥35 kg/m²
with at least one obesity-related comorbidity, are defined
as being morbidly obese. The data set used for the pre-
sent analysis was a cross-sectional study of 1,017 mor-
bidly obese Caucasian individuals, collected prospectively
between November 28th, 2005 and September 16th,
2008, at the Morbid Obesity Centre in the county of
Vestfold, Norway. The study was approved by the
Regional Committee for Medical Research Ethics
(S-05175) and was performed in accordance with the
Declaration of Helsinki [22].
MS was diagnosed in patients with at least three of
the following characteristics [1]; elevated waist circum-
ference (≥102 cm in men and ≥88 cm in women), ele-
vated fasting triglycerides (≥1.7 mmol/l), elevated blood
pressure, elevated fasting glucose (≥5.6 mmol/l) or dia-
betes, or reduced HDL-cholesterol (<1.0 mmol/l in men
and <1.3 mmol/l in women). Type 2 diabetes was diag-
nosed in patients who had a prior history of type 2 dia-
betes or a fasting serum glucose level ≥7.0 mmol/l [23].
The data has been published previously, and further
details on definitions, physical examination and labora-
tory analyses can be found elsewhere [17].
Path model
Based on previous research the following seven explana-
tory variables were included in a statistical model for
the occurrence of MS; age, type 2 diabetes (T2DM),
PTH, vit D, calcium, phosphate and magnesium. The
relations between the variables, as suggested in the lit-
erature, are summarized in a path model (Figure 1). The
effects of the explanatory variables are decomposed into
a direct effect on MS and various possible indirect
effects, mediated by among others PTH. The proposed
path model is based on the following.
It is well known that age is associated with an
increased odds of MS and T2DM, while T2DM is asso-
ciated with increased risk of MS [6,17]. Low serum mag-
nesium has been shown to be a predictor of both MS
and T2DM [10,17,24,25] while low phosphate and
increased levels of albumin-corrected calcium is related
to increased incidence of MS [25-27]. Vit D is also asso-
ciated with MS [7,8,11].
PTH has been shown to be associated with increased
odds for MS, even after adjustment for vit D [17]. The
synthesis and secretion of PTH is regulated by serum
levels of calcium and phosphate [20], while obesity,
older age and reduced levels of calcium and vit D are all
associated with higher levels of PTH [20,28,29]. Studies
have shown that serum concentrations of vit D and
magnesium influence PTH levels [19,20], while low
serum magnesium has been shown to inhibit PTH
secretion [19]. Finally, both vit D and phosphate are
associated with calcium [20].
Arrows in a path diagram represent suggested depen-
dencies between variables, and absence of an arrow
between two variables indicates that these variables are
considered statistically independent in the model. All
hypothesized direct and indirect relations among mea-
sured variables can be read off the path diagram.
Statistical analysis
Descriptive statistics are presented as mean and stan-
dard deviation (SD) or frequency and percentage (%).
Chi square and independent samples T-tests were used
for univariate comparisons.
The parameters of our proposed path model (Figure 1)
were estimated using path analysis. Analytical methods in
clinical research often rely on multiple regression models
with one main outcome variable, and a set of explanatory
variables treated on equal terms. Path analysis, in
contrast, is a multivariable method based on a model
with several linked regression equations [21]. Within this
system of equations, some of the variables can be
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considered both as outcome variables and as explanatory
variables at the same time. Path analysis is a form of
structural equation modeling, and requires that all
hypothesized dependencies between the variables are
specified in a model and depicted in a path diagram prior
to the analysis.
The path diagram formed the basis for the path analy-
sis, in which we obtain direct and indirect effect esti-
mates simultaneously by combining four regression
equations, each with one of the following variables as
the outcome: MS, PTH, calcium and T2DM. In order to
assess the validity of the underlying assumption of line-
arity in the separate linear and logistic regressions, gen-
eralized additive models (GAM) [30] were fitted prior to
the path analysis.
We also wanted to test for gender differences. As a
preliminary analysis, we therefore fitted the path model
separately for men and women. This analysis suggested
possible gender differences for several paths, and para-
meters for such possible gender effects were included in
the full model and estimated.
All continuous variables were standardized prior to
the analysis. Standardization allows one to compare the
relative importance of various effects in a model,
whereas using original variables allows for comparison
across studies [31]. We mainly report results as standar-
dized regression coefficients, but include the unstandar-
dized coefficients for comparison. For binary outcomes
the corresponding regression coefficients equal the loga-
rithm of the odds ratio (OR).
For pathways consisting of only continuous variables,
e.g. calcium®PTH®MS, indirect effects can be found
by multiplication of the regression coefficients along this
pathway, while total effects can be found by summing
effects along each separate pathway connecting two vari-
ables, e.g. calcium®MS plus calcium®PTH®MS.
When binary outcomes are involved somewhere along a
pathway, the situation is less straightforward; regression
coefficients have different interpretations in linear and
logistic regression, and merely adding and multiplying
regression coefficients is not meaningful.
Statistical analyses were performed in R 2.11 [32]. The
path analyses were done using Bayesian estimation pro-
cedures [33] by running WinBUGS [34] from within
R. Bayesian estimation gives estimates of regression coef-
ficients and corresponding credibility intervals (CrIs),
which are comparable to frequentistic confidence inter-
vals. Considerations of statistical significance were based
on the coverage of the credibility intervals. Comparison
of path models was done by the deviance information cri-
terion (DIC); lower numbers of DIC are preferable [35].
Further details of the Bayesian model specification and
model fitting can be found in Appendix A.
Results
On the variables in our path model we had complete
observations for 971 (95.5%) patients, which were
included in the statistical analyses. Clinical and bio-
chemical characteristics are summarized in Table 1.
There were 655 (67.5%) women, and all men and
Metabolic syndrome
MagnesiumVitamin DCalciumPhosphatePTH
Diabetes
Age
Figure 1 Path diagram showing hypothesized relationships between variables, decomposed into direct and indirect effects. Path
diagram showing hypothesized relationships between variables as suggested in the literature, decomposed into direct and indirect effects. The
indirect pathways between the included explanatory variables and MS were hypothesized to be mediated by PTH. Arrows represent
dependencies between variables. Absence of an arrow between two variables indicates that the variables are considered to be statistically
independent in the model.
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women had a waist circumference >102 cm and >88 cm,
respectively. In total 662 (68.1%) had MS (65.4% and
73.3% for women and men, respectively, p = 0.013).
Of the 246 patients who had T2DM 241 (98%) also
had MS.
Path model estimation
We first performed a path analysis of the model in Figure 1
separately for men and women as a preliminary analysis to
explore possible gender differences. Besides an apparent
gender difference in the direct effects of age on both PTH
and MS, and in the direct effect of PTH on MS, also phos-
phate showed a possibly significant gender difference in
the direct path to MS (data not shown). Parameters for
these possible gender differences were included along
their respective paths in the overall path model, resulting
in a model with reduced DIC compared to a model with-
out such gender differences (from 7182 to 7172). Remov-
ing statistically non-significant direct paths from this
larger model reduced the DIC further (from 7172 to
7142). Regression results from this final, optimal model,
expressed as standardized regression coefficients and CrIs,
are shown in Table 2. Unstandardized results are included
for reference.
MS
Besides diabetes and age, only PTH and phosphate had
significant direct effects on MS. The effect of T2DM
was by far the strongest, while the estimated direct
effect of PTH was 0.36 (95% CrI [0.15,0.57]). This value
implies that a 1 SD increase in PTH (2.3 pmol/l) results
in an increase of 0.36 in the log odds of MS. Due to a
significant gender difference, this direct effect of PTH
on MS was significant for women only.
Direct effects of age and phosphate were 0.31 (95%
CrI [0.13,0.50]) and 0.28 (95% CrI [0.10,0.47]), respec-
tively, implying that an increase in 1 SD in age or phos-
phate (12 years and 0.17 mmol/l, respectively) results in
an increase in the log OR of MS by approximately one
third. Due to significant gender differences, these direct
effects on MS were also only significant for women.
Even though the 95% CrI for the gender difference for
age on MS included zero, removing this gender effect
from the model actually resulted in a model with an
increased DIC, arguing for keeping it in the model.
PTH
All proposed explanatory variables of MS had significant
direct effects on PTH. As a consequence, they all have
significant indirect effects on MS for women. The stron-
gest direct effects on PTH were vit D and phosphate;
-0.27 (95% CrI [-0.33,-0.21]) and -0.26 (95% CrI [-0.32,-
0.20]), respectively. This value implies that an increase
of 1 SD in vit D or phosphate (22.0 nmol/l and 0.17
mmol/l, respectively) corresponds to a mean decrease of
approximately one fourth SD in PTH (-0.58 pmol/l).
However, phosphate also has an indirect effect on PTH,
mediated through calcium. The direct effect of phos-
phate on calcium is 0.27 (95% CrI [0.21, 0.33]), while
the direct effect of calcium on PTH is -0.09 (95% CrI
[-0.15,-0.04]). The total effect of phosphate on PTH is
thus -0.26+(-0.09)*0.27 = -0.28; about a 10% increase
compared to the direct effect alone. While the effect of
phosphate on PTH, and in result MS, is partly mediated
through calcium, the effect of magnesium on MS is
mediated through both PTH and T2DM. Due to T2DM
being a binary outcome along one of the pathways, this
total effect cannot be quantified.
The direct effect of age on PTH was 0.20 (95% CrI
[0.13,0.27]). For the direct effect of age on PTH there
was also a significant gender effect, resulting in this
direct effect of age being significant for women only.
For women, the total effect of age on MS is thus split
into a direct path and two indirect paths; one via T2DM
and one via PTH.
MS, PTH and gender differences
A summary of the statistically significant paths for men
and women is presented in Figure 2, while Table 3 sum-
marizes the direct and indirect effects the various pro-
posed explanatory variables has on MS.
Discussion
Previous reports have addressed the effect of PTH on
MS, and discussed whether the variable should be
adjusted for when estimating the effect of other possible
predictors of MS [14-17]. Our path analysis on morbidly
obese subjects suggests a possible mediating role of
PTH in the association between MS and various demo-
graphic variables and biomarkers. Significant gender dif-
ferences indicate, however, that this mediating effect is
only significant for women.
Table 1 Characteristics of patients according to gender
Gender
Variables Variables Total Female Male P
Number of patients 971 655 316
Age (years) 42 (12) 41 (12) 44 (12) 0.001
Waist (cm) 133 (14) 129 (13) 141 (14) <0.001
MS 661 (68%) 429 (65%) 232 (73%) 0.013
Type 2 diabetes 247 (25%) 147 (22) 100 (32%) 0.002
PTH (pmol/l) 5.8 (2.3) 5.8 (2.3) 5.9 (2.4) 0.597
25(OH)D (nmol/l) 52 (22) 54 (22) 50 (21) 0.009
Magnesium (mmol/l) 0.84 (0.07) 0.84 (0.07) 0.85 (0.07) 0.522
Calcium (mmol/l) 2.35 (0.07) 2.36 (0.07) 2.35 (0.07) 0.024
Phosphate (mmol/l) 1.09 (0.17) 1.10 (0.16) 1.06 (0.17) <0.001
Data are means (SD) for continuous variables and n (%) for categorical
variables.
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Table 2 Bayesian path analysis with gender effects. For a select variables the direct effect is for women only,
accompanied by an estimation of significant gender difference and corresponding effect for males. The
unstandardized effect estimates are odds ratios (OR) for binary outcomes
VARIABLES ESTIMATES USING
STANDARDIZED VARIABLES
UNSTANDARDIZED
EFFECT ESTIMATES
Outcome
variable
Explanatory
Variable
Direct effect
(95% CrI)
Gender diff.
(95% CrI)
Corresp. effect for males
(95% CrI)
Direct effect
(95% CrI)
Effect for males
(95% CrI)
MSbin Diabetes 3.47
(2.65,4.42)
32.0
(14.2,83.4)
Age 0.31
(0.13,0.50)
-0.29
(-0.64,0.04)
0.02
(-0.25,0.30)
1.03
(1.01,1.04)
1.00
(0.98,1.03)
PTH 0.36
(0.15,0.57)
-0.43
(-0.77,-0.11)
-0.07
(-0.32,0.19)
1.17
(1.07,1.28)
0.97
(0.87,1.09)
Phosphate 0.28
(0.10,0.47)
-0.42
(-0.76,-0.05)
-0.14
(-0.41,0.12)
5.32
(1.79,17.39)
0.42
(0.08,2.10)
PTHc Age 0.20
(0.13,0.27)
-0.18
(-0.29,-0.06)
0.03
(-0.07,0.12)
0.04
(0.03,0.05)
0.005
(-0.013,0.023)
Magnesium 0.12
(0.06,0.18)
3.76
(2.00,5.59)
Vitamin D -0.27
(-0.33,-0.21)
-0.028
(-0.034,-0.022)
Phosphate -0.26
(-0.32,-0.20)
-3.57
(-4.38,-2.81)
Calcium* -0.09
(-0.15,-0.04)
-3.17
(-5.13,-1.19)
Calcium*c Phosphate 0.27
(0.21,0.33)
1.31
(1.23,1.39)
Diabetesbin Magnesium -0.76
(-0.93,-0.59)
0.000
(0.000,0.0002)
Age 0.88
(0.71,1.07)
1.08
(1.06,1.09)
binbinary outcome (logistic regression).
ccontinuous outcome (linear regression).
*Albumin corrected.
Metabolic syndrome
MagnesiumVitamin DCalciumPhosphatePTH
Diabetes
Age
Figure 2 Path diagram showing the observed direct effects between variables using path analysis. Path diagram showing statistically
significant direct paths in a hypothesized path diagram (Figure 1). Dotted lines imply significant effects for women only.
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Path model specification
The use of path diagrams and analysis of structural
models is a potentially valuable tool for increasing bio-
logical understanding [36], and is expanding in the
fields of epidemiology and medicine, including studies
of MS [37-39].
The crucial task in path analysis is to formulate a plau-
sible path diagram based on existing evidence and cur-
rent biological concepts. Path analysis is a multivariable
regression technique and the hypothesized directions of
arrows in the path diagram will thus affect results: Chan-
ging the direction of an arrow changes a variable’s status
from explanatory to outcome, or vice versa.
We recognize that while more complex than tradi-
tional multiple regression models, our path model is still
only one of many plausible models that can be hypothe-
sized in order to explain the underlying biological
mechanisms. There are several possible variables not
included in our model that might influence estimates
and considerations of direct and indirect effects, for
example creatinine [40]. Both alternative path models
and expanded versions of the present model, including
more and/or other variables and plausible paths, are
valuable topics for future research.
PTH, MS and gender differences
The hypothesized mediating role of PTH in relation to
MS was partly confirmed in our data. Of the included
explanatory variables, several did not have significant
direct paths to MS, while all but one had significant
direct paths to PTH, implying significant indirect effects
on MS. There was, however, a significant gender differ-
ence in the direct path from PTH to MS, implying that
this direct effect was only significant for women. The
proposed mediating role of PTH is as such a possible
property for women only.
The gender specific association between PTH and MS
might be explained by some of the properties of the
patient population. Men have a higher prevalence of
diabetes than women (32% vs 22%) and MS (73% vs
65%) (Table 1). The diabetes prevalence difference
might be of particular interest since diabetic patients
with MS have lower PTH levels than MS-subjects with-
out diabetes [17]. In addition, the pathophysiology of
MS may differ between genders [41]. Male patients also
had significantly lower levels of phosphate and calcium.
The increased effect of age on PTH was also only sig-
nificant for women. For men there was no direct effect
on MS of neither PTH nor age. In other studies, increas-
ing PTH levels seem to be associated with MS in older
men, but not in women and younger men [12,13,42].
This is contrary to our findings. However, previous stu-
dies have not found significant relationships between
PTH, vit D and MS in morbidly obese subjects [18].
PTH as a mediator?
Weight reduction and higher intakes of calcium and
vitamin D have been found to be associated with
decreases in PTH levels [28,29]. So even though the
direct effect of calcium and vitamin D on MS are not
significant, both may still have clinical value, given
their indirect effects, mediated through PTH. It has
been claimed that PTH is associated with MS, while
vit D is not [17]. According to our analysis, this only
holds true if considering direct effects only. Lowering
PTH, for example through medication or through
dietary modulation or weight reduction, is potentially
a way of reducing the risk of MS; increasing intake of
vit D and calcium might indirectly achieve similar
results.
Exactly why lowered PTH values are associated with
reduced odds of MS is unclear. A recently published
link between PTH and MS in older men was explained
by insulin resistance, high blood pressure, hyperglycemia
and low HDL-cholesterol [12,13]. The hypothesis that
PTH may be involved in the pathogenesis of hyperten-
sion is also supported by a prospective population based
cohort study [43]. The positive correlation between
serum PTH and blood pressure has been confirmed
[17], but not between PTH and insulin resistance [7],
blood glucose or blood lipids [12,13].
Whether lowering of serum PTH does indeed trans-
late into beneficial effects on MS remains unclear, and
cannot be assessed in a cross-sectional study; whether
PTH is a mediator in the biological processes cannot be
confirmed by a study like ours. We want to emphasize
the need for experimental studies to assess the molecu-
lar mechanisms, as well as the importance of interpret-
ing results from observational studies with caution
concerning causality. However, with PTH regulative
medications like cinacalcet (Sensipar/Mimpara, Amgen
Inc., Thousand Oaks, CA) on the market, a randomized
controlled trial can be carried out.
Table 3 Type of effect of various explanatory variables
on MS
Type of effect on MS
Variable Women Men
PTH Direct -
T2DM Direct Direct
Age Direct and indirect through PTH and
T2DM
Indirect through
T2DM
Phosphate Direct and indirect through PTH and
calcium
-
Calcium Indirect through PTH -
Vitamin D Indirect through PTH -
Magnesium Indirect through PTH and T2DM Indirect through
T2DM
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Phosphate
Lower levels of phosphate have been shown to be asso-
ciated with the components of MS [44], and are usually
related to increased risk of MS [25-27]. This does not
appear to be the case in our data of morbidly obese
patients. For women increasing levels of phosphate was
associated with increased risk of MS. Due to a signifi-
cant gender difference, there was no direct effect of
phosphate on MS for men, nor an indirect effect
mediated through PTH. An explanation for this gender
difference could be that men had significantly lower
phosphate levels than women (Table 1).
Magnesium, T2DM and MS
Low serum magnesium has been shown to be associated
with T2DM and MS [10,17,24,25], but when adjusting
for T2DM in multiple regression analyses, the associa-
tion between magnesium and MS is no longer statisti-
cally significant [17]. However, this does not mean that
serum magnesium is unrelated to MS. It merely implies
that the effects are possibly indirect rather than direct.
Our path analysis shows that there is an indirect effect
of magnesium on MS, mediated through T2DM; lower-
ing magnesium levels will increase the odds of T2DM
which again increases the odds of MS.
Bayesian analysis
Bayesian methods has only been used to a limited
extent in clinical research, but the WinBUGS software
has made Bayesian methods more easily available [45].
While traditional frequentistic analyses are based on
normality assumptions and central limit theory, Baye-
sian analyses are based on assumptions of prior distri-
butions and on simulation techniques. In Bayesian
models non-normality and non-linearity is easily dealt
with. They are also flexible with respect to several types
of variables [45].
Strengths and limitations
The current study is based on a relatively large, homo-
genous sample of morbidly obese individuals, which is
further strengthened by the prospective collection and
registration of data. In our model all variables are effec-
tively adjusted for one another, and all parameters esti-
mated simultaneously, reducing the effect of multiple
testing.
The study had some limitations. First, the cross-
sectional design makes it impossible to establish cause-
effect relationships. Though potentially graphically
convincing and appealing, a path model cannot itself
assess causality. The directions of arrows in the path
diagram are a crucial point. For this, micro-level bio-
chemical experiments are needed. Second, the results
may not be valid in non-white populations or among
non-obese subjects. Finally, we cannot exclude the pos-
sibility that referral of patients to a tertiary care center
might have introduced a selection bias.
Conclusions
The results of our study, combining current biological
concepts and empirical data, suggest that PTH is a
plausible mediator in the association between MS and
various demographic variables and biomarkers, includ-
ing vit D, phosphate and magnesium, in morbidly
obese individuals. Due to significant gender differences,
in our data this mediating role was only significant for
women. Mechanisms like metabolic pathways are com-
plex, and graphical models like the current can be use-
ful tools.
Appendix A
All path estimates presented in this paper were calcu-
lated using Markov Chain Monte Carlo simulation
(MCMC) in WinBugs [34], run through the R wrapper
R2WinBUGS [46] in the freeware R 2.11 [32]. Stochastic
simulations in WinBUGS can be unstable, particularly
for complex hierarchical models, and diffuse prior distri-
butions add to the problem [47]. We used vague prior
probability distributions for all parameters [33], but the
common advise of standardizing variables resolved
instability issues in our case. We used 3 parallel MCMC
chains in the calculations, each based on 10,000 itera-
tions from which the first 5,000 were discarded as a
“burn-in”. This ensured an estimated potential scale
reduction (EPSR) of approximately 1 for all parameters,
implying convergence [48].
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